Interleukin-13: A pivotal target against influenza-induced exacerbation of chronic lung diseases

Shastri MD 1 , Allam VSRR 2 , Shukla SD 3 , Jha NK 4 , Paudel KR 5 , Peterson GM 6 Show all authors , Patel RP 6 , Hansbro PM 5 , Chellappan DK 7 , Dua K 8

Affiliations 

  • 1 School of Pharmacy and Pharmacology, University of Tasmania, Hobart 7005, Australia. Electronic address: Madhur.Shastri@utas.edu.au
  • 2 Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden
  • 3 Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, Australia; Faculty of Health, Australian Research Centre in Complementary and Integrative Medicine, University of Technology Sydney, Ultimo, NSW 2007, Australia
  • 4 Department of Biotechnology, School of Engineering & Technology (SET), Sharda University, Greater Noida, UP, India
  • 5 Centre for Inflammation, Centenary Institute, Sydney, NSW 2050, Australia; School of Life Sciences, Faculty of Science, University of Technology Sydney, NSW 2007, Australia
  • 6 School of Pharmacy and Pharmacology, University of Tasmania, Hobart 7005, Australia
  • 7 Department of Life Sciences, School of Pharmacy, International Medical University (IMU), Kuala Lumpur, Malaysia
  • 8 Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, Australia; Centre for Inflammation, Centenary Institute, Sydney, NSW 2050, Australia; Faculty of Health, Australian Research Centre in Complementary and Integrative Medicine, University of Technology Sydney, Ultimo, NSW 2007, Australia. Electronic address: Kamal.Dua@uts.edu.au
Life Sci, 2021 Oct 15;283:119871.
PMID: 34352260 DOI: 10.1016/j.lfs.2021.119871

Abstract

Non-communicable, chronic respiratory diseases (CRDs) affect millions of individuals worldwide. The course of these CRDs (asthma, chronic obstructive pulmonary disease, and cystic fibrosis) are often punctuated by microbial infections that may result in hospitalization and are associated with increased risk of morbidity and mortality, as well as reduced quality of life. Interleukin-13 (IL-13) is a key protein that regulates airway inflammation and mucus hypersecretion. There has been much interest in IL-13 from the last two decades. This cytokine is believed to play a decisive role in the exacerbation of inflammation during the course of viral infections, especially, in those with pre-existing CRDs. Here, we discuss the common viral infections in CRDs, as well as the potential role that IL-13 plays in the virus-induced disease pathogenesis of CRDs. We also discuss, in detail, the immune-modulation potential of IL-13 that could be translated to in-depth studies to develop IL-13-based therapeutic entities.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications